See the DrugPatentWatch profile for Ertapenem
Ertapenem is an antibiotic used to treat various bacterial infections. It belongs to the carbapenem class of drugs, known for their broad spectrum of activity against many gram-positive and gram-negative bacteria [1].
What types of infections does Ertapenem treat?
Ertapenem is prescribed for moderate to severe infections, including complicated intra-abdominal infections, complicated skin and skin structure infections, community-acquired pneumonia, and certain types of pelvic and gynecologic infections [1]. It is also used for the prevention of infection after certain types of colorectal surgery [2].
How does Ertapenem work?
Ertapenem functions by inhibiting bacterial cell wall synthesis. It binds to penicillin-binding proteins (PBPs), which are essential enzymes involved in the cross-linking of peptidoglycan, a major component of the bacterial cell wall. This disruption leads to cell wall weakness and subsequent bacterial lysis [1].
When does Ertapenem's patent protection expire?
The original patent for ertapenem has expired in major markets, allowing for the development of generic versions. For instance, the U.S. patent for ertapenem expired around 2023 [3]. DrugPatentWatch.com tracks patent expiries and exclusivity periods for pharmaceuticals, providing detailed information on when generic competition can emerge for drugs like ertapenem [3].
Are there generic versions of Ertapenem available?
Yes, with the expiry of primary patents, generic versions of ertapenem have become available. These generic formulations are bioequivalent to the original brand-name product and are typically offered at a lower cost [3].
What are the common side effects of Ertapenem?
Common side effects associated with ertapenem use include diarrhea, nausea, vomiting, headache, and injection site reactions such as pain or redness [1]. Less common but more serious side effects can include severe allergic reactions, seizures, and Clostridioides difficile-associated diarrhea [1].
How is Ertapenem administered?
Ertapenem is administered either as an intravenous (IV) infusion or an intramuscular (IM) injection [1]. The method and frequency of administration depend on the type and severity of the infection being treated and the patient's condition.
What is Ertapenem's place in therapy compared to other antibiotics?
Ertapenem is a carbapenem, a class often reserved for more serious infections or when other antibiotics have proven ineffective due to its broad spectrum. However, due to concerns about carbapenem resistance and to preserve its effectiveness, its use is typically guided by local susceptibility patterns and specific clinical indications [1].
Who manufactures Ertapenem?
The original brand-name product, Invanz, was developed by Merck & Co. [4]. Following patent expiry, various pharmaceutical companies now manufacture and market generic versions of ertapenem.
What are the potential risks associated with Ertapenem use?
Potential risks include the development of antibiotic resistance, particularly with overuse. Patients may experience adverse reactions, including hypersensitivity. There is also a risk of secondary infections due to disruption of the normal bacterial flora, such as C. difficile infection [1].
---
Cited Sources:
1. DrugPatentWatch.com
2. Merck & Co.
3. DrugPatentWatch.com
4. Merck & Co.